Autophagic responses to hypoxia and anticancer therapy in head and neck cancer

Pathology Research and Practice

Volumn 211, Issue 2, 2015, Pages 101-108

  Wu, Haiwei ^a   Huang, Shengyun ^a   Zhang, Dongsheng ^a  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

Anticancer therapy; Autophagy; Head and neck squamous cell carcinoma; Hypoxia

Indexed keywords

AZD 8055; BECLIN 1; CAMPTOTHECIN; CETUXIMAB; CHLOROQUINE; CISPLATIN; DACTOLISIB; DEGUELIN; ETOPOSIDE; FLUOROURACIL; HYDROXYCHLOROQUINE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 1BETA; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MESSENGER RNA; METHOTREXATE; NVPBGT 226; PROTEIN BCL 2; TEMOZOLOMIDE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

APOPTOSIS; AUTOPHAGY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CARCINOGENESIS; CHEMOSENSITIVITY; DNA DAMAGE; DOWN REGULATION; EPITHELIUM DYSPLASIA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MOUTH SQUAMOUS CELL CARCINOMA; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RADIOSENSITIZATION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVIEW; TUMOR GROWTH; TUMOR MICROENVIRONMENT; UNFOLDED PROTEIN RESPONSE; UPREGULATION; ADJUVANT CHEMORADIOTHERAPY; ANOXIA; CARCINOMA, SQUAMOUS CELL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HEAD AND NECK NEOPLASMS; ONCOGENESIS AND MALIGNANT TRANSFORMATION; PATHOPHYSIOLOGY; PHYSIOLOGY; RADIATION RESPONSE;

ANOXIA; ANTINEOPLASTIC AGENTS; AUTOPHAGY; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY, ADJUVANT; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; NEOPLASTIC PROCESSES;

EID: 84977771310     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2014.11.010     Document Type: Review

References (95)

1. Siddiqui F., Gwede C.K. Head and neck cancer in the elderly population. Semin. Radiat. Oncol. 2012, 22:321-333.
2. Farris C., Petitte D.M. Head, neck, and oral cancer update. Home Healthc. Nurse 2013, 31:322-328.
3. Machiels J.P., Lambrecht M., Hanin F.X., et al. Advances in the management of squamous cell carcinoma of the head and neck. F1000Prime Rep. 2014, 6:44.
4. Sawicki M., Szudy A., Szczyrek M., et al. Molecularly targeted therapies in head and neck cancers. Otolaryngol. Pol. 2012, 66:307-312.
5. Pietrocola F., Izzo V., Niso-Santano M., et al. Regulation of autophagy by stress-responsive transcription factors. Semin. Cancer Biol. 2013, 10.1016/j.semcancer.
6. Cukierman E., Bassi D.E. The mesenchymal tumor microenvironment: a drug-resistant niche. Cell Adh. Migr. 2012, 6:285-296.
7. Wouters B.G., Weppler S.A., Koritzinsky M., et al. Hypoxia as a target for combined modality treatments. Eur. J. Cancer 2002, 38:240-257.
8. Janssen H.L., Haustermans K.M., Balm A.J., et al. Hypoxia in head and neck cancer: how much, how important?. Head Neck 2005, 27:622-638.
9. Rouschop K., Wouters B.G. Regulation of autophagy through multiple independent hypoxic signaling pathways. Curr. Mol. Med. 2009, 9:417-424.
10. Hu Y.L., Jahangiri A., DeLay M., et al. Tumor cell autophagy as an adaptive response mediating resistance to treatments such as antiangiogenic therapy. Cancer Res. 2012, 72:4294-4300.
11. Eskelinen E.L. The dual role of autophagy in cancer. Curr. Opin. Pharmacol. 2011, 11:294-300.
12. Zhang H., Bosch-Marce M., Shimoda L.A., et al. Mitochondrial autophagy is an HIF-1-dependent adaptive metabolic response to hypoxia. J. Biol. Chem. 2008, 283:10892-10903.
13. Kirkin V., McEwan D.G., Novak I., et al. A role for ubiquitin in selective autophagy. Mol. Cell 2009, 34:259-269.
14. Xie Z., Klionsky D.J. Autophagosome formation: core machinery and adaptations. Nat. Cell Biol. 2007, 9:1102-1109.
15. Hu Y.L., DeLay M., Jahangiri A., et al. Hypoxia-induced autophagy promotes tumor cell survival and adaptation to antiangiogenic treatment in glioblastoma. Cancer Res. 2012, 72:1773-1783.
16. Chen N., Karantza V. Autophagy as a therapeutic target in cancer. Cancer Biol. Ther. 2011, 11:157-168.
17. Vigneswaran N., Wu J., Song A., et al. Hypoxia-induced autophagic response is associated with aggressive phenotype and elevated incidence of metastasis in orthotopic immunocompetent murine models of head and neck squamous cell carcinomas (HNSCC). Exp. Mol. Pathol. 2011, 90:215-225.
18. Zheng H.Y., Zhang X.Y., Wang X.F., et al. Autophagy enhances the aggressiveness of human colorectal cancer cells and their ability to adapt to apoptotic stimulus. Cancer Biol. Med. 2012, 9:105-110.
19. Carew J.S., Kelly K.R., Nawrocki S.T. Autophagy as a target for cancer therapy: new developments. Cancer Manag. Res. 2012, 4:357-365.
20. Ouyang L., Shi Z., Zhao S., et al. Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis. Cell Prolif. 2012, 45:487-498.
21. White E., DiPaola R.S. The double-edged sword of autophagy modulation in cancer. Clin. Cancer Res. 2009, 15:5308-5316.
22. Chen N., Debnath J. Autophagy and tumorigenesis. FEBS Lett. 2010, 584:1427-1435.
23. Leng S., Hao Y., Du D., et al. Ursolic acid promotes cancer cell death by inducing Atg5-dependent autophagy. Int. J. Cancer 2013, 10.1002/ijc.28301.
24. Zhang J., Chiu J., Zhang H., et al. Autophagic cell death induced by resveratrol depends on the Ca2+/AMPK/mTOR pathway in A549 cells. Biochem. Pharmacol. 2013, 86:317-328.
25. Fujimoto K., Hanson P.T., Tran H., et al. Autophagy regulates pancreatic beta cell death in response to Pdx1 deficiency and nutrient deprivation. J. Biol. Chem. 2009, 284:27664-27673.
26. Young A.R., Narita M., Ferreira M., et al. Autophagy mediates the mitotic senescence transition. Genes Dev. 2009, 23:798-803.
27. Aita V.M., Liang X.H., Murty V.V., et al. Cloning and genomic organization of Beclin 1, a candidate tumor suppressor gene on chromosome 17q21. Genomics 1999, 59:59-65.
28. Qu X., Yu J., Bhagat G., et al. Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. J. Clin. Invest. 2003, 112:1809-1820.
29. Choi J., Jung W., Koo J.S. Expression of autophagy-related markers beclin-1, light chain 3A, light chain 3B and p62 according to the molecular subtype of breast cancer. Histopathology 2013, 62:275-286.
30. Jiang Z.F., Shao L.J., Wang W.M., et al. Decreased expression of Beclin-1 and LC3 in human lung cancer. Mol. Biol. Rep. 2012, 39:259-267.
31. Wan X.B., Fan X.J., Huang P.Y., et al. Aurora-A activation, correlated with hypoxia-inducible factor-1α, promotes radiochemoresistance and predicts poor outcome for nasopharyngeal carcinoma. Cancer Sci. 2012, 103:1586-1594.
32. Kapoor V., Paliwal D., Baskar S.S., et al. Deregulation of Beclin 1 in patients with tobacco-related oral squamous cell carcinoma. Biochem. Biophys. Res. Commun. 2012, 422:764-769.
33. Kang R., Wang Z.H., Wang B.Q., et al. Inhibition of autophagy-potentiated chemosensitivity to cisplatin in laryngeal cancer Hep-2 cells. Am. J. Otolaryngol. 2012, 33:678-684.
34. Freudlsperger C., Burnett J.R., Friedman J.A., et al. EGFR-PI3K-AKT-mTOR signaling in head and neck squamous cell carcinomas: attractive targets for molecular-oriented therapy. Expert Opin. Ther. Targets 2011, 15:63-74.
35. Li Q., Song X.M., Ji Y.Y., et al. The dual mTORC1 and mTORC2 inhibitor AZD8055 inhibits head and neck squamous cell carcinoma cell growth in vivo and in vitro. Biochem. Biophys. Res. Commun. 2013, 440:701-706.
36. D'Amato V., Rosa R., D'Amato C., De Placido S., Bianco R., et al. The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models. Br. J. Cancer 2014, 110:2887-2895.
37. Toustrup K., Sørensen B.S., Alsner J., et al. Hypoxia gene expression signatures as prognostic and predictive markers in head and neck radiotherapy. Semin. Radiat. Oncol. 2012, 22:119-127.
38. Adams J.M., Difazio L.T., Rolandelli R.H., et al. HIF-1: a key mediator in hypoxia (Review). Acta Physiol. Hung. 2009, 96:19-28.
39. Arjamaa O., Nikinmaa M. Oxygen-dependent diseases in the retina: role of hypoxia-inducible factors. Exp. Eye Res. 2006, 83:473-483.
40. Semenza G.L. HIF-1 and mechanisms of hypoxia sensing. Curr. Opin. Cell Biol. 2001, 13:167-171.
41. Brennan P.A., Mackenzie N., Quintero M. Hypoxia-inducible factor 1α in oral cancer. J. Oral Pathol. Med. 2005, 34:385-389.
42. Alves L.R., Fraga C.A., Oliveira M.V., et al. High HIF-1α expression genotypes increase odds ratio of oral cancer. Head Neck Oncol. 2011, 4:87.
43. Liang X., Yang D., Hu J., et al. Hypoxia inducible factor-1alpha expression correlates with vascular endothelial growth factor-C expression and lymphangiogenesis/angiogenesis in oral squamous cell carcinoma. Anticancer Res. 2008, 28:1659-1666.
44. Rademakers S.E., Lok J., van der Kogel A.J., et al. Metabolic markers in relation to hypoxia; staining patterns and colocalization of pimonidazole, HIF-1α, CAIX, LDH-5, GLUT-1, MCT1 and MCT4. BMC Cancer 2011, 11:167.
45. Kappler M., Taubert H., Holzhausen H.J., et al. Immunohistochemical detection of HIF-1α and CAIX in advanced head-and-neck cancer. Strahlenther. Onkol. 2008, 184:393-399.
46. Wang X., Schneider A. HIF-2α-mediated activation of the epidermal growth factor receptor potentiates head and neck cancer cell migration in response to hypoxia. Carcinogenesis 2010, 31:1202-1210.
47. Aebersold D.M., Burri P., Beer K.T., et al. Expression of hypoxia-inducible factor-1α a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res. 2001, 61:2911-2916.
48. Bose P., Brockton N.T., Dort J.C. Head and neck cancer: from anatomy to biology. Int. J. Cancer 2013, 133:2013-2023.
49. Adachi M., Cui C., Dodge C.T., et al. Targeting STAT3 inhibits growth and enhances radiosensitivity in head and neck squamous cell carcinoma. Oral Oncol. 2012, 48:1220-1226.
50. Toustrup K., Sørensen B.S., Nordsmark M., et al. Development of a hypoxia gene expression classifier with predictive impact for hypoxic modification of radiotherapy in head and neck cancer. Cancer Res. 2011, 71:5923-5931.
51. Cosse J.P., Michiels C. Tumour hypoxia affects the responsiveness of cancer cells to chemotherapy and promotes cancer progression. Anticancer Agents Med. Chem. 2008, 8:790-797.
52. Scherz-Shouval R., Elazar Z. Regulation of autophagy by ROS: physiology and pathology. Trends Biochem. Sci. 2011, 36:30-38.
53. Chinnadurai G., Vijayalingam S., Gibson S.B. BNIP3 subfamily BH3-only proteins: mitochondrial stress sensors in normal and pathological functions. Oncogene 2008, 27:S114-S127.
54. Bellot G., Garcia-Medina R., Gounon P., et al. Hypoxia-induced autophagy is mediated through hypoxia-inducible factor induction of BNIP3 and BNIP3L via their BH3 domains. Mol. Cell Biol. 2009, 29:2570-2581.
55. Azad M.B., Gibson S.B. Role of BNIP3 in proliferation and hypoxia-induced autophagy: implications for personalized cancer therapies. Ann. N.Y. Acad. Sci. 2010, 1210:8-16.
56. Band M., Joel A., Hernandez A., et al. Hypoxia-induced BNIP3 expression and mitophagy: in vivo comparison of the rat and the hypoxia-tolerant mole rat, Spalax ehrenbergi. The FASEB J. 2009, 23:2327-2335.
57. Azad M.B., Chen Y., Henson E.S., et al. Hypoxia induces autophagic cell death in apoptosis-competent cells through a mechanism involving BNIP3. Autophagy 2008, 4:195-204.
58. Mazure N.M., Pouysségur J. Hypoxia-induced autophagy: cell death or cell survival?. Curr. Opin. Cell Biol. 2010, 22:177-180.
59. Papandreou I., Lim A.L., Laderoute K., et al. Hypoxia signals autophagy in tumor cells via AMPK activity, independent of HIF-1, BNIP3, and BNIP3L. Cell Death Differ. 2008, 15:1572-1581.
60. Yang Y.L., Ji C., Bi Z.G., et al. Deguelin induces both apoptosis and autophagy in cultured head and neck squamous cell carcinoma cells. PloS One 2013, 10.1371/journa l.pone.
61. Healy S.J., Gorman A.M., Mousavi-Shafaei P., et al. Targeting the endoplasmic reticulum-stress response as an anticancer strategy. Eur. J. Pharmacol. 2009, 625:234-246.
62. Suh D.H., Kim M.K., Kim H.S., et al. Unfolded protein response to autophagy as a promising druggable target for anticancer therapy. Ann. N.Y. Acad. Sci. 2012, 1271:20-32.
63. Wang X.J., Yu J., Wong S.H., et al. A novel crosstalk between two major protein degradation systems: regulation of proteasomal activity by autophagy. Autophagy 2013, 9:1500-1508.
64. Korolchuk V.I., Mansilla A., Menzies F.M., et al. Autophagy inhibition compromises degradation of ubiquitin-proteasome pathway substrates. Mol. Cell 2009, 33:517-527.
65. Zang Y., Thomas S.M., Chan E.T., et al. The next generation proteasome inhibitors carfilzomib and oprozomib activate prosurvival autophagy via induction of the unfolded protein response and ATF4. Autophagy 2012, 8:1873-1874.
66. Zang Y., Thomas S.M., Chan E.T., et al. Carfilzomib and ONX 0912 inhibit cell survival and tumor growth of head and neck cancer and their activities are enhanced by suppression of Mcl-1 or autophagy. Clin. Cancer Res. 2012, 18:5639-5649.
67. Shaid S., Brandts C.H., Serve H., et al. Ubiquitination and selective autophagy. Cell Death Differ. 2012, 20:21-30.
68. Liu B., Wen X., Cheng Y. Survival or death: disequilibrating the oncogenic a nd tumor suppressive autophagy in cancer. Cell Death Dis. 2013, 4:e892.
69. Hoyer-Hansen M., Jaattela M. Autophagy: an emerging target for cancer therapy. Autophagy 2008, 4:574-580.
70. Liu Y., Levine B. Autosis and autophagic cell death: the dark side of autophagy. Cell Death Differ. 2014, 10.1038/cdd.2014.143.
71. Gutierrez E., Richardson D.R., Jansson P.J. The anti-cancer agent, Dp44mT, overcomes pro-survival autophagy by two mechanisms: persistent induction of autophagosome synthesis and impairment of lysosomal integrity. J. Biol. Chem. 2014, pii: jbc.M114.599480.
72. Lee Y.R., Wu W.C., Ji W.T., et al. Reversine suppresses oral squamous cell carcinoma via cell cycle arrest and concomitantly apoptosis and autophagy. J. Biomed. Sci. 2012, 19:1-12.
73. Trédan O., Galmarini C.M., Patel K., et al. Drug resistance and the solid tumor microenvironment. J. Natl. Cancer Inst. 2007, 99:1441-1454.
74. Rebucci M., Michiels C. Molecular aspects of cancer cell resistance to chemotherapy. Biochem. Pharmacol. 2013, 85:1219-1226.
75. Bai J., Guo X.G., Bai X.P. Epidermal growth factor receptor-related DNA repair and radiation-resistance regulatory mechanisms: a mini-review. Asian Pac. J. Cancer Prev. 2012, 13:4879-4881.
76. Rohwer N., Cramer T. Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways. Drug Resist. Updat. 2011, 14:191-201.
77. Zois C.E., Koukourakis M.I. Radiation-induced autophagy in normal and cancer cells: towards novel cytoprotection and radio-sensitization policies?. Autophagy 2009, 5:442-450.
78. Palumbo S., Comincini S. Autophagy and ionizing radiation in tumors: the "Survive or not Survive" dilemma. J. Cell Physiol. 2013, 228:1-8.
79. Katayama M., Kawaguchi T., Berger M.S., et al. DNA damaging agent-induced autophagy produces a cytoprotective adenosine triphosphate surge in malignant glioma cells. Cell Death Differ. 2006, 14:548-558.
80. Notte A., Leclere L., Michiels C. Autophagy as a mediator of chemotherapy-induced cell death in cancer. Biochem. Pharmacol. 2011, 82:427-434.
81. Tsai C.W., Lai F.J., Sheu H.M., et al. WWOX suppresses autophagy for inducing apoptosis in methotrexate-treated human squamous cell carcinoma. Cell Death Dis. 2013, 4:e792.
82. Chaachouay H., Ohneseit P., Toulany M., et al. Autophagy contributes to resistance of tumor cells to ionizing radiation. Radiother. Oncol. 2011, 99:287-292.
83. Li Y., Xu L., Cai A., et al. The effect of autophagy on the radioresistance of human adenocarcinoma A549 cell in hypoxia condition. Zhongguo Fei Ai Za Zhi 2012, 15:638-641.
84. Yuk J.M., Shin D.M., Song K.S., et al. Bacillus calmette-guerin cell wall cytoskeleton enhances colon cancer radiosensitivity through autophagy. Autophagy 2010, 6:46-60.
85. Pang X.L., He G., Liu Y.B., et al. Endoplasmic reticulum stress sensitizes human esophageal cancer cell to radiation. World J. Gastroenterol. 2013, 19:1736-1748.
86. Palumbo S., Pirtoli L., Tini P., et al. Different involvement of autophagy in human malignant glioma cell lines undergoing irradiation and temozolomide combined treatments. J. Cell Biochem. 2012, 113:2308-2318.
87. Cerniglia G.J., Karar J., Tyagi S., et al. Inhibition of autophagy as a strategy to augment radiosensitization by the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235. Mol. Pharmacol. 2012, 82:1230-1240.
88. Chang K.Y., Tsai S.Y., Wu C.M., et al. Novel phosphoinositide 3-kinase/mTOR dual inhibitor, NVP-BGT226, displays potent growth-inhibitory activity against human head and neck cancer cells in vitro and in vivo. Clin. Cancer Res. 2011, 17:7116-7126.
89. Farazi T.A., Hoell J.I., Morozov P., et al. MicroRNAs in human cancer. Adv. Exp. Med. Biol. 2013, 774:1-20.
90. Babu J.M., Prathibha R., Jijith V.S., et al. A miR-centric view of head and neck cancers. Biochim. Biophys. Acta 2011, 1816:67-72.
91. Yoshizawa J.M., Wong D.T. Salivary microRNAs and oral cancer detection. Methods Mol. Biol. 2013, 936:313-324.
92. Pan B., Yi J., Song H. MicroRNA-mediated autophagic signaling networks and cancer chemoresistance. Cancer Biother. Radiopharm. 2013, 10.1089/cbr.2012.1460.
93. Zhai H., Fesler A., Ju J. MicroRNA: a third dimension in autophagy. Cell Cycle 2013, 12:246-250.
94. Xu N., Zhang J., Shen C., et al. Cisplatin-induced downregulation of miR-199a-5p increases drug resistance by activating autophagy in HCC cell. Biochem. Biophys. Res. Commun. 2012, 423:826-831.
95. Yi H., Liang B., Jia J., et al. Differential roles of miR-199a-5p in radiation-induced autophagy in breast cancer cells. FEBS Lett. 2013, 587:436-443.